Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

75.47EUR
17 Jun 2019
Change (% chg)

-- (--)
Prev Close
€75.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,411,787
52-wk High
€80.44
52-wk Low
€67.39

Select another date:

Fri, Jun 7 2019

Photo

France's Sanofi bets on new CEO to drive sluggish drug sales

ZURICH In veteran drug salesman Paul Hudson, Sanofi's 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

NEWSMAKER-France's Sanofi bets on new CEO to drive sluggish drug sales

ZURICH, June 7 In veteran drug salesman Paul Hudson, Sanofi's 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

Drugmaker Sanofi hires Hudson from Novartis as CEO

PARIS Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher.

UPDATE 3-Drugmaker Sanofi hires Hudson from Novartis as CEO

* Hudson from Novartis to join Sanofi from Sept. 1 * Current CEO Brandicourt to retire * Shares up almost 5 percent (Adds share price, comment) By Matthias Blamont PARIS, June 7 Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher. Hudson, who is British, will take over on Sept. 1,

CORRECTED-UPDATE 2-Drugmaker Sanofi appoints Novartis' Hudson as CEO

PARIS, June 7 Sanofi has appointed Novartis executive Paul Hudson to replace CEO Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday.

CORRECTED-Sanofi appoints Paul Hudson as CEO to replace retiring Brandicourt

PARIS, June 7 French pharma giant Sanofi appointed Paul Hudson as chief executive to replace Olivier Brandicourt, who will retire in September, the company said on Friday.

Exclusive: Sanofi poised to appoint Novartis' Hudson as CEO

PARIS Sanofi is poised to appoint Paul Hudson, a top executive with Switzerland's Novartis, to become the French drugmaker's next CEO from Sept. 1, a source familiar with the decision told Reuters on Thursday.

FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

UPDATE 1-U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

April 26 The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Select another date: